Open AccessP551: A PHASE 3, RANDOMIZED, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53‐MUTANT ACUTE MYELOID LEUKEMIA
Author(s) -
Daver N. G.,
Vyas P.,
Chao M. P.,
Xing G.,
Renard C.,
Ramsingh G.,
Sallman D. A.,
Wei A. H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845092.62208.b7
Subject(s) - medicine , azacitidine , tolerability , myeloid leukemia , venetoclax , oncology , hypomethylating agent , chemotherapy , leukemia , adverse effect , chronic lymphocytic leukemia , biology , biochemistry , gene expression , gene , dna methylation